NYSE:JNJ - Johnson & Johnson Stock Price, News, & Analysis

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Johnson & Johnson announced a quarterly dividend on Wednesday, January 2nd. Shareholders of record on Tuesday, February 26th will be paid a dividend of $0.90 per share on Tuesday, March 12th. This represents a $3.60 dividend on an annualized basis and a yield of 2.75%. The ex-dividend date of this dividend is Monday, February 25th. View Johnson & Johnson's Dividend History.

Johnson & Johnson announced that its board has initiated a stock repurchase plan on Monday, December 17th 2018, which permits the company to buyback $5,000,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization permits the company to purchase up to 1.5% of its shares through open market purchases. Shares buyback plans are typically a sign that the company's board believes its shares are undervalued.

Johnson & Johnson (NYSE:JNJ) issued its quarterly earnings results on Tuesday, April, 17th. The company reported $2.06 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.00 by $0.06. The company earned $20.01 billion during the quarter, compared to analyst estimates of $19.50 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company's quarterly revenue was up 12.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.83 earnings per share. View Johnson & Johnson's Earnings History.

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, January 22nd 2019. View Earnings Estimates for Johnson & Johnson.

Johnson & Johnson will be holding an earnings conference call on Tuesday, January 22nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Johnson & Johnson updated its FY18 earnings guidance on Monday, December, 17th. The company provided earnings per share guidance of $8.13-8.18 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.16. The company issued revenue guidance of $81.0-81.4 billion, compared to the consensus revenue estimate of $81.39 billion.Johnson & Johnson also updated its FY 2018 guidance to $8.13-8.18 EPS.

13 equities research analysts have issued 1-year price targets for Johnson & Johnson's stock. Their forecasts range from $110.00 to $160.00. On average, they expect Johnson & Johnson's share price to reach $139.5455 in the next year. This suggests a possible upside of 6.8% from the stock's current price. View Analyst Price Targets for Johnson & Johnson.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Johnson & Johnson in the last year. There are currently 1 sell rating, 5 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Johnson & Johnson.

News articles about JNJ stock have trended positive recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Johnson & Johnson earned a news impact score of 2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future.

Johnson & Johnson saw a decrease in short interest in December. As of December 31st, there was short interest totalling 15,719,662 shares, a decrease of 19.9% from the December 14th total of 19,633,883 shares. Based on an average trading volume of 15,979,892 shares, the days-to-cover ratio is currently 1.0 days. Currently, 0.6% of the company's shares are sold short. View Johnson & Johnson's Current Options Chain.

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG).

Johnson & Johnson's stock is owned by many different of institutional and retail investors. Top institutional shareholders include DNB Asset Management AS (0.06%), Hexavest Inc. (0.06%), Gateway Investment Advisers LLC (0.05%), Confluence Investment Management LLC (0.04%), Nisa Investment Advisors LLC (0.04%) and BTIM Corp. (0.03%). Company insiders that own Johnson & Johnson stock include Alex Gorsky, Charles Prince, Dominic J Caruso, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

JNJ stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Atalanta Sosnoff Capital LLC, Sit Investment Associates Inc., USS Investment Management Ltd, Highland Capital Management LLC, Hexavest Inc., Moreno Evelyn V and Capital Investment Advisors LLC. Company insiders that have sold Johnson & Johnson company stock in the last year include Alex Gorsky, Joaquin Duato, Michael E Sneed, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Insider Buying and Selling for Johnson & Johnson.

JNJ stock was bought by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, DNB Asset Management AS, Ferguson Wellman Capital Management Inc., Weather Gauge Advisory LLC, QCI Asset Management Inc. NY, Centre Asset Management LLC, Nisa Investment Advisors LLC and Nachman Norwood & Parrott Inc. View Insider Buying and Selling for Johnson & Johnson.

Shares of JNJ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of JNJ stock can currently be purchased for approximately $130.69.

Johnson & Johnson has a market capitalization of $343.52 billion and generates $76.45 billion in revenue each year. The company earns $1.30 billion in net income (profit) each year or $7.30 on an earnings per share basis. Johnson & Johnson employs 134,000 workers across the globe.

The official website for Johnson & Johnson is http://www.jnj.com.

Johnson & Johnson's mailing address is ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ, 08933. The company can be reached via phone at 732-524-0400.